B cell-activating factor enhances interleukin-6 and interleukin-10 production by ODN-activated human B cells.
We aim to investigate the additive value of B cell-activating factor (BAFF) when added to oligodeoxynucleotides (ODN)-activated B cells with respect to TLR-9, CD69, MHC-II expression, IL-6 and IL-10 secretion and B cell cycling. Therefore, B cells from healthy individuals were incubated under the following conditions: (1) B cells with medium, (2) B cells with ODN 0.5 μm, (3) B cells with BAFF 20 μm and (4) B cells with both ODN 0.5 μm and BAFF 20 μm. We found that addition of BAFF did not enhance the expression of TLR-9, CD69 and MHC-II in ODN-activated B cells. Incubation of B cells with BAFF and ODN together leads to a marked elevation of IL-6 and IL-10 levels compared to ODN alone. Synthesis and mitosis were higher in B cells stimulated by BAFF than in B cells stimulated by ODN. These findings suggest that both BAFF and TLR-9 contribute independently to B cell function.
Department of Internal Medicine A, Bnai Zion Medical Center, Faculty of Medicine, Technion, Haifa, Israel.
D
D
Yehudai
A
A
Snir
R
R
Peri
K
K
Halasz
T
T
Haj
M
M
Odeh
A
A
Kessel
D015703:Antigens, CD / Q000235:genetics / Q000378:metabolism; D000945:Antigens, Differentiation, T-Lymphocyte / Q000235:genetics / Q000378:metabolism; D053264:B-Cell Activating Factor / Q000276:immunology / Q000494:pharmacology*; D001402:B-Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D002454:Cell Differentiation / Q000187:drug effects; D018899:CpG Islands / Q000235:genetics / Q000276:immunology; D004347:Drug Interactions; D005786:Gene Expression Regulation / Q000187:drug effects; D000949:Histocompatibility Antigens Class II / Q000235:genetics / Q000378:metabolism; D006801:Humans; D016753:Interleukin-10 / Q000096:biosynthesis* / Q000276:immunology; D015850:Interleukin-6 / Q000096:biosynthesis* / Q000276:immunology; D037181:Lectins, C-Type / Q000235:genetics / Q000378:metabolism; D008213:Lymphocyte Activation / Q000187:drug effects; D009838:Oligodeoxyribonucleotides / Q000276:immunology / Q000494:pharmacology*; D061251:Primary Cell Culture; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics; D051217:Toll-Like Receptor 9 / Q000235:genetics / Q000378:metabolism*; D000099192:CD69 Antigens
D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D053264:B-Cell Activating Factor; D000949:Histocompatibility Antigens Class II; D016753:Interleukin-10; D015850:Interleukin-6; D037181:Lectins, C-Type; D009838:Oligodeoxyribonucleotides; D051217:Toll-Like Receptor 9; D000099192:CD69 Antigens; C508600:IL6 protein, human; C495371:TLR9 protein, human; C505719:TNFSF13B protein, human